Business Context and Reporting Period
Company: Integer Holdings Corporation (ITGR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Integer is a leading medical device contract development and manufacturing organization (MDO) serving cardiac rhythm management, neuromodulation, and cardio/vascular markets. The company operates as a single reportable segment following the divestiture of its Non-Medical segment (Electrochem) in October 2024. Integer is executing a strategy to exit the Portable Medical market by 2026 while pursuing "tuck-in" acquisitions to expand capabilities in high-growth medtech sectors.
Key Financial Metrics (Fiscal Year 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Total Sales | $1,716.6 million | $1,555.7 million |
| Gross Profit | $459.0 million | $409.9 million |
| Gross Margin | 26.7% | 26.3% |
| Operating Income | $208.2 million | $163.3 million |
| Net Income (Continuing Ops) | $121.1 million | $89.1 million |
| Diluted EPS (Continuing Ops) | $3.40 | $2.64 |
| Operating Cash Flow | $205.2 million | $180.2 million |
| Total Debt Outstanding | $1.0 billion (Principal) | $974.0 million (Principal) |
| Cash and Equivalents | $46.5 million | $23.7 million |
| Working Capital | $443.9 million | $382.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 10% year-over-year, driven by strong demand in Cardio & Vascular (up 14%) and Cardiac Rhythm Management & Neuromodulation (up 8%) segments. Growth was supported by new product ramps and contributions from the Pulse and InNeuroCo acquisitions.
- Profitability: Operating income rose 28% to $208.2 million. Gross margin expanded 40 basis points to 26.7% due to sales volume leverage and manufacturing efficiencies.
- Divestiture: Completed the sale of Electrochem Solutions (Non-Medical segment) in October 2024 for $50.0 million. Results are reported as discontinued operations, which recorded a net loss of $1.2 million for 2024.
- Acquisitions: Acquired Pulse Technologies (January 2024) to enhance micro-machining capabilities. Subsequent to year-end, acquired Precision Coating (January 2025) and entered an agreement to acquire VSi Parylene (February 2025).
- Tax Rate: Effective tax rate increased to 18.0% from 15.4% in 2023, primarily due to the implementation of the OECD Pillar II Global Minimum Tax and the expiration of a Malaysia tax holiday.
Guidance, Outlook, and Risks
- Outlook: Management expects Portable Medical sales to wind down with final exit in 2025. Capital expenditures for 2025 are projected to be between $110 million and $120 million, focused on manufacturing upgrades and IT systems.
- Liquidity: The company maintains $668.7 million in available borrowing capacity under its Revolving Credit Facility. Management believes cash flows and borrowing capacity are sufficient to meet obligations for the next 12 months.
- Convertible Notes: The 2028 Convertible Notes ($500 million principal) are currently convertible at the option of holders through March 31, 2025, as stock price conditions were met. The company intends to refinance conversion obligations using revolver capacity if necessary.
- Key Risks:
- Customer Concentration: Top three customers (Abbott, Boston Scientific, Medtronic) accounted for 47% of 2024 sales.
- Supply Chain: Reliance on limited suppliers for critical raw materials (e.g., platinum, gold, titanium) and exposure to geopolitical disruptions and tariffs.
- Regulatory: Subject to strict FDA and EU-MDR regulations; potential for product recalls or regulatory audits.
- Cybersecurity: Ongoing risk of cyber-attacks impacting operations and data integrity.
Investor Verification Checklist
- Convertible Note Conversion: Verify if holders of the 2028 Convertible Notes elect to convert prior to March 31, 2025, and the impact on cash liquidity or share dilution.
- Acquisition Integration: Monitor the integration progress and financial contribution of Pulse Technologies and the subsequent Precision Coating acquisition.
- Portable Medical Exit: Track the timeline and cost implications of the planned exit from the Portable Medical market, expected to conclude in 2025.
- Customer Concentration: Assess any changes in order volumes from the top three customers, which represent nearly half of total revenue.
- Tax Rate Volatility: Monitor the impact of the OECD Pillar II Global Minimum Tax on future effective tax rates and net income.